Due to their rapid dispersion in the gastrointestinal tract, they maximize drug absorption and minimize potential side effects without lowering drug bioavailability. Multi-particulate systems also reduce variations in gastric emptying rates and overall transit times. Thus, intra and inter-subject variability of plasma profiles, which are common with single-unit regimens, are minimized. 2) In general, pellets are preferable to tablets, because they are not easily influenced by physiological factors (dose dumping) or individual lot differences.
3) A multi-particulate system using spherical granules as seed cores is one method for controlling drug release. This system was composed of a drug layer and outer sustained release layers. Drug release rate decreases as the thickness of the release controlled layer increases. But it took a long time to make the thick layer. Therefore, to shorten the manufacturing time, powder coating is effective in obtaining a thick layer which decreases the drug release rate. In general, the powder coating layer is very porous compared with the liquid one. 4) For making the powder coating layer dense, a combination of Lubliwax (WAX) and magnesium stearate (Mg-St) was adopted, and additional heat-treatment effects on the drug release rate were studied. In general, WAX is used as a matrix agent for sustaining drug release with heat-treatment. 5, 6) In this study, the WAX is used as a layer for sustaining drug release. As the outer Mg-St layer could prevent the melted WAX from aggregating between particles, heat-treatment could be performed for prolonging the release rate. In the case of using WAX as the layer type, the lag-time increased as the WAX layer thickness increased. 7) For obtaining a zeroorder release profile of the drug, we had to mix pellets with different WAX thickness. But zero-order drug release could be performed using a multi-layer with heat-treatment without mixing pellets in this study. Since the solubility of sodium valproate (VP-Na) in water is high and a drug release profile is influenced by only a slight difference in the sustained release layer, we can evaluate the release properties clearly. Therefore, VP-Na was used as a model drug in this study.
taneous spraying of a binder solution. A binder solution (4.55% EC 10 ethanol solution) was prepared by dissolving EC 10 in ethanol with magnetic stirring, because the VP-Na was very sensitive to humidity. The binder solution was continuously sprayed on the moving drug cores using a peristaltic pump. Powder addition was started at the same time the binder solution spraying started. At fixed intervals, fixed weights of the powder composition were layered onto the drug cores. Resultant sustained release pellets were dried in an oven at 40°C for 20 h prior to heat-treatment.
In Vitro Release Testing Release testing was carried out by the Japanese Pharmacopoeia (JP XIV) rotating basket method (50 rpm.; purified water 900 ml; 37°C). Purified water was used as a dissolution medium. The concentration of VP-Na was measured using an electric conductivity meter (Digital conduct meter, Model, CM-15A, DKK-TOA Corporation, Japan). MDT 11) (mean dissolution time) was used as an index of the drug release rate, and these values were calculated using the computer program "MULTI".
Heat-Treatment Heat-treatment was performed using a CF-granulator under a rotating bottom plate (Table 4) . Heat-treatment effects (temperature and time) were investigated using pellets composed of 6 sustained release layers ( Table 1 , formula No. 4). After powder coating, the resulting pellets were cured at 70, 75 or 85°C for 2-30 min by a CF-Granulator to prolong the release rate.
Microscopy of Pellets The surface morphology of several pellets was observed with an optical microscope (OLYMPUS (VANOX), Tokyo, Japan). Cross-sections of coated pellets with or without heat-treatment were examined by scanning electron microscopy (SEM, JSM-T20, JEOL, Ltd., Japan).
Results and Discussion
A CF-Granulator 12) was an appropriate machine for powder coating. Keeping the balance between the feeding rate of the layering powder and the binder solution is very important for powder coating using a CF-Granulator. The feeding rate of powder and binder was optimized in order to prevent agglomeration and powder loss. Particle size distributions of the coated pellets prepared in this study were sharp (mean diameters were about 1400 mm ).
Morphology of Several Coating Process Pellets Microscopic evaluation of pellets was performed. Figure 1 shows optical photographs of pellets produced at each stage of the coating process. Figure 1 (A) shows a photograph of the seed cores. On the surface of the seed cores, VP-Na was coated (B) (drug cores). On the surface of drug cores, the WAX and the Mg-St were coated (Table 1, formula No. 3) (C). According to visual observations, the surfaces of pellets are all smooth, indicating that the balance of powder feeding and the binder addition were in good conditions in this study.
Effect of the Loading Weight of Water-Insoluble Powders on Release Profiles The effect of varying coating levels of the WAX and the Mg-St on release profiles is shown in Figs. 2 and 3 , respectively. Table 1 shows the formula of these pellets (formula No. 1 and No. 2). It is known that the drug release rate is considerably influenced by the coating level of the water-insoluble powder. 13) According to the release profiles of Fig. 2 (WAX) and Fig. 3 (Mg-St), the Mg-St was more effective in prolonging the release rate of a drug from coated-pellets than WAX. But, in both cases, high loadings of water-insoluble powders were required to achieve long-sustained release.
Effect of Heat-Treatment Conditions on Drug Release There are several curing techniques, i.e. heat, UV irradiation and chemical reaction using catalysts. 14) In general, curing reduces the rate of drug release and results in stable drug release profiles. 15) In this study, heat-treatment was performed using a CF-granulator under a rotating bottom plate under the conditions shown in Table 4 .
(1) Effect of Heat-Treatment Temperature and Time on the Drug Release Rate: Figure 4 shows the dissolution profiles of VP-Na from VP-Na sustained release pellets (formula No.4 (Table 1) ) which were heat-treated with various heat-treatment temperatures and times. As heat-treatment temperature increased, the drug release rate decreased. Heattreatment for 10 min is sufficient for obtaining a stable release layer. Further heat-treatment at 70 and 75°C did not affect the drug release rate.
However, in the case of pellets heat-treated for 30 min at 85°C, the release pattern was changed. It was found that heat-treatment retarded drug release, and its effect was related to heat-treatment temperature and time.
The rate of drug release from coated-pellets composed of triple layers (Table 2 , formula SWS-3) decreased dramatically after heat-treatment (Fig. 5 ). This may be because heattreatment retarded drug release, mainly by decreasing the porosity of the WAX layer.
(2) Scanning Electron Microscopy (SEM) of Coated Pellets: A cross-section of the coated pellets ( Table 2 , formula SWS-3) was examined by scanning electron microscopy (SEM) (Fig. 6 ). SEM analysis indicated that heat-treatment caused the WAX to melt, and the distributed WAX formed a film-like structure (shown with an arrow in Fig. 6 ). Table 1 . 
ment. Figures 6(B) and (C) are cross-sections of the layer of pellets with heat-treatment at 75 and 85°C, respectively. On SEM observations, the volume of the WAX layer decreased, and the WAX layer became dense with an increase in heattreatment temperature. It was found that the film-like WAX layer could have a great effect in prolonging the drug release rate.
Effect of Structural Difference of Release Controlled Layers on Drug Release Rate
Even if compositions are the same, the drug release rate can be affected by structural differences in the release controlled layer. The total weights of coated WAX and Mg-St in formula M-2, WS, MS-1, SWS-1 and WSWS are the same (WAX/Mg-Stϭ1/1; Table 2 ), but the structures of their sustained release layers are different from one another, leading to individual MDT values. The MDT value (no-treatment) of M-2 is 0.7 h. This value is almost the same as WS (MDTϭ0.7 h). In the case of a multilayer type (more than 3 layers), the MDT values of SWS-1 (MDTϭ1.5 h) and WSWS (MDTϭ1.3 h) were longer than with the other types. Figure 7 shows the three types of release controlled layers; that is, (A) single layer type (Table 2 , formula M-2 (MDTϭ 0.7 h)), (B) double layer type (Table 2, formula MS-1 (MDTϭ1.0 h)) and (C) triple layer type (Table 2 , formula SWS-1 (MDTϭ1.5 h)). The numbers (i.e. 32, 64) in Fig. 7 are the weight of the coated powder. In these three types, the weight of the Mg-St used is the same as that of the WAX used. According to the listed MDT values, it was found that drug release rates were influenced significantly by structural differences of the release controlled layer. Among these three types, the triple layer type (sandwich type) was most effective in prolonging the drug release rate. This was because the uniform WAX layer between Mg-St layers was effective for achieving a dense layer. Table 1 .
Effect of Component Difference of Release Controlled Layers on Drug Release Rate

Fig. 3. Effect of Coating Level of Mg-St on VP-Na Release from the Pellets
Coating level: ᭜ 40 g, 80 g, ᭝ 120 g and ᭺ 160 g. Formula: No. 2 in Table 1 . ᭜ without heat-treatment, ᮀ heat-treatment at 75°C, ᭺ heat-treatment at 85°C. Formula : SWS-3 in Table 2. release controlled layer and the loading weight of water-insoluble polymers was the same, the characteristics of drug release would depend on the different components of the release controlled layer.
(1) Single Layer Type: Judging from the MDT values of formulas M-1, M-2 and M-3 (Table 5 ), the effect of the mixture layer of the WAX and the Mg-St on prolonging the drug release rate was not significantly observed. Among the samples of the single layer type tried in this study, as the WAX/ Mg-St ratio decreased, the MDT value increased. In the case of single layer type, heat-treatment could not be performed because of the aggregation between particles.
(2) Double Layer Type: Table 2 shows the formulas of a release controlled layer. The MDT values of a double layer type (formula WS, MS-1, MS-2 and MS-3) are shown in Table 5 . In all the double layer types prepared in this study, heat-treatment could be performed at 85°C. The formula of WS and MS-1 was the same, but the effect on prolonging the release rate was higher in the case of MS-1, where the WAX was mixed with the Mg-St. As the mixing ratio of the WAX increased, the effect on prolonging the release rate decreased in the case of non-heat-treatment. The MDT values increased as heat-treatment temperature increased.
(3) Triple Layer Type: Table 2 shows the formulas of the release controlled layer. The MDT values of the sandwich type (triple layer type) (formula SWS-1, -2, -3) are shown in Table 5 . The sandwich type layer was more effective in obtaining sustained release than the other types.
As mentioned above, heat-treatment was operated by a CF-Granulator (Table 4 ). The external Mg-St layer inhibits the aggregation between particles caused by the melting WAX. Heat-treatment was effective in prolonging the release rate, even at 75°C. The weight ratio of the Mg-St to the WAX was changed to control the drug release rate. In the case of formulas SWS-1 and SWS-2, heat-treatment at 85°C could not be performed because of the aggregation between particles. Heat-treatment at 85°C could be performed only in the case of the formula SWS-3, i.e. the ratio of the weight of the WAX to the Mg-St was the smallest. This was because that the WAX did not move into the outer layer at this ratio. The preparation of formula SWS-3, which was heat-treated at 85°C, was the most effective in prolonging the drug release rate among the preparations tested in this study. A thin WAX layer between Mg-St layers of adequate thickness is effective in obtaining a dense layer with heat-treatment. The heat-conductivity to the WAX layer depends on the thickness. As the thickness of the WAX layer increases, the heatconductivity to the WAX layer decreases, and it is hard to obtain a uniform dense layer. Furthermore, as the thickness of the WAX layer increases, aggregation problems between par- Table 2 . The numbers in Fig. 7 are the weights which were used for preparing the various sustained release pellets of VP-Na. ticles occur. Shortening the Release Lag-Time It is often observed that the slower the drug release rate, the longer the lag-time of drug release.
10) The duration of the lag time increased with increasing heat-treatment temperature and time.
11) Figure 8 shows the release profiles of VP-Na powder and the three kinds of pellets with heat-treatment at 85°C. The release rate of three sustained release pellets were significantly slower than that of VP-Na powder, but a lag time of drug release was observed. For shortening drug release lag time, more multi-thin-layer type pellets were prepared. In the case of pellets with four sustained release layers (WSWS), zero order drug release occurred without a drug release lag time after heat-treatment at 75°C (Fig. 9) . Figure 10 shows the release profiles of VP-Na from the sustained release pellets composed of 5 layers with the MgSt (S) and the WAX (W), in the order of SWSWS. The formula is shown in Table 2 (formula SWSWS). Sustained release pellets with heat-treatment at 75°C showed a sigmoid release profile with an initial lag time, but this lag time significantly diminished after heat-treatment at 85°C. Figure 11 shows the hypothesis to explain why the drug is released without a lag time and with nearly zero order kinetics. First of all, melted WAX moved into the Mg-St layer through the gap of the Mg-St powder. It is presumed some of the VP-Na dispersed in the melted WAX with an increase in heat-treatment temperature, and VP-Na then moved into the release controlled layer. Also, the VP-Na concentration gradient in the sustained release layer of VP-Na-sustained release pellets was good for diminishing the lag time and producing a nearly zero order release. The structural change of the sustained release layer by heat-treatment strongly affected drug release. Thus, a slow and zero-order drug release was obtained with heat-treatment at 85°C, while a first-order release pattern with a drug release lag-time was obtained with heat-treatment at 75°C. Proper design of the heat-treated ᭜ VP-Na powder: The release profile of the VP-Na from the VP-Na powder. ᮀ MS-2: The release profile of the VP-Na from the pellets (Formula: MS-2 in Table 2 ). ᭺ MS-3: The release profile of the VP-Na from the pellets (Formula: MS-3 in Table 2 ). ᭡ SWS-3: The release profile of the VP-Na from the pellets (Formula: SWS-3 in Table 2 ). multi-layer was proposed as a way to obtain approximate long-sustained zero-order release.
Conclusion
Sustained release preparations of VP-Na (a highly watersoluble drug) could be prepared by constructing layers composed of the WAX and Mg-St powders by a CF-Granulator. The layer which was prepared by powder coating was effective in prolonging the drug release rate, but in the case of using a highly water-soluble drug, it took a lot of weight of the coating powder. However, the combination of the WAX, the Mg-St layer and heat-treatment appears to retard drug release, mainly by decreasing the porosity of the WAX layer. The Mg-St layer was useful for protecting the aggregation between particles caused by the melted WAX.
Drug release profiles were influenced by structural differences and component differences of sustained release layers. The sandwich type layer was more effective in sustaining drug release than other types. Heat-treatment was very effective at the temperature of 85°C. Slow and zero-order drug release was obtained by a multi-thin-layer with heat-treatment. This is because the structure of the sustained release layer changed with heat-treatment at 85°C.
